Navigation Links
Astellas and DNDi to collaborate on new drug discovery research for the treatment of NTDs
Date:6/12/2012

[Tokyo, Japan and Geneva, Switzerland, June 12, 2012] - Astellas Pharma Inc. (Tokyo:4503, "Astellas") and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide. The agreement is a first critical step in Astellas' new strategy to enter into the field of NTDs, with DNDi as its first partner.

Under the agreement, Astellas will provide DNDi with a selection of original compounds. These will be screened at the Swiss Tropical and Public Health Institute in Switzerland. The pharmaceutical profiles of the compounds were studied in pre-clinical and/or clinical stages at Astellas. DNDi will conduct reprofiling of the compounds to test their anti-protozoan activities and assess their potential as new anti-protozoan candidates for the three targeted diseases.

'We welcome Astellas as a new partner both in the field of NTDs and as part of a product development partnership. In the field of neglected diseases, and particularly for the most neglected leishmaniasis, Chagas disease, and sleeping sickness this new partnership reinforces the critical mass of engaged actors necessary to address urgent patient needs' said Dr Bernard Pcoul, Executive Director of DNDi.

'Astellas believes that this joint research method leads to the early entry into the development stage of new potential agents if promising compounds are identified as candidates. Astellas will seek the way to contribute drug discovery research for NTDs based on Astellas' advanced science ', says Dr Shin-ichi Tsukamoto, Senior Vice President of Astellas Drug Discovery Research.


'/>"/>

Contact: Violaine Daellenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. BGI and Aspera collaborate on high-speed data exchange to advance genome research
3. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
4. Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012
5. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
6. Unexpected discovery reveals a new mechanism for how the cerebellum extracts signal from noise
7. Discovery offers insight into treating viral stomach flu
8. Breast cancer risk gene discovery fast tracked by new technology
9. Tales from the crypt lead researchers to cancer discovery
10. New discovery may lead to effective prevention and treatment of graft-versus-host dsease
11. Stomata development in plants unraveled -- a valuable discovery for environmental research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose ... lengthy trial and error process by finding the right antidepressant faster. CNSDose ... the doctor-patient relationship through a personalized approach to treatment. , A ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs of ... Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old male ... conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is a ...
(Date:5/18/2017)... , ... May 17, 2017 , ... NDA Partners Chairman ... and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit ... his position at Eurofins and Cardinal Health, he was former Chief Operating Officer at ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is honored that ... for Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role ...
Breaking Biology Technology: